Category: Immunotherapy Melanoma

ScienceDaily (Oct. 1, 2012) — Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient’s immune system to fight the deadly cancer. A batch of the immune system’s killer T cells will be removed from the patient and genetically modified in a…

Myxoma virus is a decidedly nasty customer, particularly if you’re a rabbit. Or, it turns out, a human melanoma cell. However, recent studies have shown the virus is not known to infect human cells, raising the prospect of conscripting it in the battle against skin cancer. That said, not everyone is going to be happy…

VIENNA (IMNG) – Combination therapy with a BRAF inhibitor and a MEK inhibitor extended progression-free survival by more than 3 months in patients with BRAF V600 mutated metastatic melanoma, early clinical findings suggest.”This is the first kinase-kinase combination to show enhanced antitumor activity over the single agent,” and the first to show that specific oncogenic…

↵* Corresponding Author: F. Stephen Hodi, Medical Oncology, Dana-Farber Cancer Inst., 450 Brookline Aveneue, Boston, MA, 02215, United States stephen_hodi@dfci.harvard.edu Abstract Purpose: Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops. Interest remains in combining targeted and immune therapies to overcome resistance and…

MELBOURNE, Australia, Oct. 25, 2012 — /PRNewswire/ — Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE® (nanoparticle albumin-bound paclitaxel).…